治疗丙肝的第二代直接抗病毒药物的经济性系统评价 点击下载
| 论文标题： | 治疗丙肝的第二代直接抗病毒药物的经济性系统评价 |
| 英文标题： | |
| 中文摘要： | 目的：系统评价治疗丙型病毒性肝炎（简称“丙肝”）的第二代直接抗病毒药物（DAAs）的药物经济学研究，为今后开展此类研究提供方法学建议，同时为医保目录调整及市场准入提供决策参考。方法：检索PubMed、Embase、TheCochraneLibrary、中国知网、万方数据库和维普数据库，收集治疗丙肝的第二代DAAs的经济学评价研究，检索时限为2015年1月－2020年1月。使用卫生经济学评价报告标准共识（CHEERS）清单评估纳入研究质量，提取资料汇总并进行定性分析。结果：共纳入14项研究，其标准符合率在79.2％～95.8％之间，属于较高质量研究。13项（92.9％）研究从付费方角度采用Markov模型及终生研究时限对比了不同治疗方案的经济性。与基于索磷布韦的第二代DAAs治疗方案比较时，所有研究结果显示，奥比帕利联合达塞布韦、艾尔巴韦/格拉瑞韦、格卡瑞韦/哌仑他韦这3种方案在目标国家的经济性更好；单因素敏感性分析显示，研究结果对于药品价格、药物病毒学应答（SVR）率和健康状态效用值3类参数较为敏感。结论：在治疗丙肝的第二代DAAs中，奥比帕利联合达塞布韦、艾尔巴韦/格拉瑞韦、格卡瑞韦/哌仑他韦这3种方案的药物经济性更好。建议今后的抗丙肝药物经济学研究采用动态模型和全社会的研究角度，对多种DAAs开展直接对比的高质量经济学研究；同时，在敏感性分析中考虑药品价格、药物SVR率和健康状态效用值等参数对基础分析结果稳健性的影响，以增加研究结果的可信度。 |
| 英文摘要： | OBJECTIVE：To systematically evaluate the pharmacoeconomic research of the second-generation direct-acting antiviral agents （DAAs）in the treatment of hepatitis C ，and to provide methodological suggestions for economic research ，and to provide decision-making reference for the adjustment of medical insurance catalogues and market access. METHODS ：Retrieved from PubMed ，EMbase，the Cochrane library ，CNKI，Wanfang database and VIP ，the pharmacoeconomic researches of the second-generation DAAs for hepatitis C were collected during Jan. 2015-Jan. 2020. The quality of included studies were evaluated with the checklist about Consolidated Health Economics Evaluation Reporting Standards （CHEERS），and the data were extracted and analyzed quantitatively. RESULTS ：A total of 14 studies were included ，and the standard coincidence rate ranged from 79.2％ to 95.8％；the overall quality was relatively high. Thirteen （92.9％）studies had compared the economics of different treatment schemes from the perspective of the payer by using the Markov model and the lifetime study time limit. Compared with the second-generation DAAs treatment schemes based on sofosbuvir ，all the research results showed that Ombitasvir combined with Dasabuvir（3D），EBR/GZR and GLE/PIB were more economical in the target countries ；single factor sensitivity analysis showed that the research results were more sensitive to the three parameters of drug price ，drug SVR rate and health status utility value. CONCLUSIONS：Among the second-generation DAAs for hepatitis C ，the three regimens of 3D，EBR/GZR and GLE/PIB are more economical. It is recommended that future research on the economics of medicines for hepatitis C adopted dynamic model and the research perspective of the whole society to carry out direct high-quality economic research on a variety of DAAs ；at the same time，considered the effects of drug price ，drug SVR rate and health status utility value on the robustness of basic analysis results in sensitivity analysis in order to increase the credibility of the research results. |
| 期刊： | 2020年第31卷第23期 |
| 作者： | 孟蕊，芮明军，马越，金敏，陈平钰 |
| 英文作者： | MENG Rui，RUI Mingjun ，MA Yue，JIN Min，CHEN Pingyu |
| 关键字： | 丙型病毒性肝炎；直接抗病毒药物；模型方法学；经济性评价；系统评价 |
| KEYWORDS： | Hepatitis C ；Direct-acting antiviral agents ； |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！